SCHEMBL4348981

SCHEMBL4348981

O=C(Nc1ccc(C(F)(F)F)cc1)N(S)c1cc(Br)cc(F)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.43
MTOR P42345 3/20 0.40
BAZ1A Q9NRL2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
RORC P51449 1/20 0.39
MAPT P10636 1/20 0.39
XBP1 P17861 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KIF11 P52732 1/20 0.39
TGM2 P21980 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TLR8 Q9NR97 1/20 0.39
P2RX1 P51575 1/20 0.38
P2RX4 Q99571 1/20 0.38
P2RX7 Q99572 1/20 0.38
TMPRSS4 Q9NRS4 1/20 0.38
MEN1 O00255 1/20 0.38
OPRK1 P41145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4345983 0.85 RAB9A (0.50) SMN1; SMN2NPC1RAB9AALDH1A1P2RX1
SCHEMBL4348538 0.85 NPC1 (0.47) SMN1; SMN2MAPTNPSR1NPC1RAB9A
SCHEMBL4348054 0.82 EPHX2 (0.45) EPHX2MTORBAZ1ASMN1; SMN2MAPT
SCHEMBL4354458 0.82 MTOR (0.42) MTORHDAC3HDAC8HDAC6TRPV1
SCHEMBL4358931 0.81 EPHX2 (0.49) EPHX2MTORBAZ1ARORCKIF11
SCHEMBL4347077 0.80 EPHX2 (0.45) EPHX2MTORBAZ1ARORCKIF11
SCHEMBL4345929 0.79 SMN1; SMN2 (0.44) SMN1; SMN2MAPTNPC1RAB9AALDH1A1
SCHEMBL4357681 0.79 KMT2A (0.36) SMN1; SMN2MAPTNPSR1NPC1RAB9A
SCHEMBL4353865 0.79 EPHX2 (0.46) EPHX2MTORBAZ1ASMN1; SMN2MAPT
SCHEMBL4354221 0.78 P2RX1 (0.46) EPHX2BAZ1AP2RX1P2RX4P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 EPHX2 769/4885MTOR 1379/4885BAZ1A 1985/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 EPHX2 627/4885MTOR 1296/4885BAZ1A 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.